Patient and healthy donor characteristics
| Characteristics | Ipilimumab 10 mg/kg | Ipilimumab 3 mg/kg | Healthy donorsa |
|---|---|---|---|
| Number of patients | 28 | 40 | 20 |
| Median age (range) | 62 (34–83) | 60 (34–80) | 38 (26–58) |
| Sex (%) | |||
| Male | 17 (61) | 29 (73) | 10 (50) |
| Female | 11 (39) | 11 (27) | 7 (35) |
| Stage of disease (%) | |||
| III (unresectable) | 0 | 1 | — |
| M1a | 3 | 0 | — |
| M1b | 4 | 5 | — |
| M1c | 21 | 34 | — |
| Median number of prior therapies (range) | 1 (0–3) | 1 (0–5) | — |
| Median LDH (range) | 209 (113–968) | 211 (117–816) | — |
| ≥Upper limit of normal (% of available LDH) | 13 (46) | 28 (70) | — |
| <Upper limit of normal (% of available LDH) | 15 (54) | 12 (30) | — |
| MDSC frequency | |||
| %HLA-DRlow/− in Lin−CD14+CD11b+ (range)b | 11.4 (3.9–24.5) | 11.2 (5.8–20.9) | 10.3 (6.4–14.3) |
| ≥14.9 (%) | 7 (25) | 7 (18) | 0 (0) |
| <14.9 (%) | 21 (75) | 33 (82) | 20 (100) |
| Median baseline ALC (range) | 1,250 (500–5,100) | 1,100 (600–8,100) | — |
| ≥1,000/μL (%) | 19 (68) | 25 (63) | — |
| <1,000/μL (%) | 9 (32) | 15 (37) | — |